G
Glenn M. Chertow
Researcher at Stanford University
Publications - 830
Citations - 94517
Glenn M. Chertow is an academic researcher from Stanford University. The author has contributed to research in topics: Kidney disease & Dialysis. The author has an hindex of 128, co-authored 764 publications receiving 82401 citations. Previous affiliations of Glenn M. Chertow include University of Groningen & Fresenius Medical Care.
Papers
More filters
Journal ArticleDOI
Validation of questionnaires to estimate physical activity and functioning in end-stage renal disease
Kirsten L. Johansen,Patricia Painter,Jane A. Kent-Braun,Alexander V. Ng,Susan Carey,Makani Da Silva,Glenn M. Chertow +6 more
TL;DR: These questionnaires designed to measure physical activity or physical functioning in the general population are valid in patients on hemodialysis and should be used to study the physical activity and rehabilitation efforts in this population further.
Journal ArticleDOI
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis : The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
Sharon M. Moe,Glenn M. Chertow,Patrick S. Parfrey,Yumi Kubo,Geoffrey A. Block,Ricardo Correa-Rotter,Tilman B. Drüeke,Charles A. Herzog,Gérard M. London,Kenneth W. Mahaffey,David C. Wheeler,Maria Stolina,Bastian Dehmel,William G. Goodman,Jürgen Floege +14 more
TL;DR: In this paper, the effects of calcimimetic cinacalcet (versus placebo) on reducing serum fibroblast growth factor-23 and whether changes in FGF23 are associated with death and cardiovascular events.
Journal ArticleDOI
Atrial natriuretic factor in oliguric acute renal failure
Julia B. Lewis,Mahmoud M. Salem,Glenn M. Chertow,Lawrence S. Weisberg,Frank McGrew,Thomas C. Marbury,Robin L. Allgren +6 more
TL;DR: Although a trend was present, there was no statistically significant beneficial effect of ANP in dialysis-free survival or reduction in Dialysis in these subjects with oliguric acute renal failure.
Journal ArticleDOI
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
David C. Wheeler,David C. Wheeler,Bergur V. Stefánsson,Niels Jongs,Glenn M. Chertow,Tom Greene,Fan Fan Hou,John J.V. McMurray,Ricardo Correa-Rotter,Peter Rossing,Robert D. Toto,C. David Sjöström,Anna Maria Langkilde,Hiddo J.L. Heerspink,Dapa-Ckd Trial Committees,Investigators +15 more
TL;DR: The relative risk reduction for the primary composite outcome with dapagliflozin was consistent in participants with type 2 diabetes and those without diabetes, with similar consistency seen across the secondary outcomes.
Journal ArticleDOI
Cystatin C and mortality risk in the elderly: the health, aging, and body composition study.
Michael G. Shlipak,Christina L. Wassel Fyr,Glenn M. Chertow,Tamara B. Harris,Stephen B. Kritchevsky,Frances A. Tylavsky,Suzanne Satterfield,Steven R. Cummings,Anne B. Newman,Linda F. Fried +9 more
TL;DR: Each quintile of cystatin C was significantly associated with increased mortality risk compared with the lowest, and results were consistent for cardiovascular and other-cause mortality, but not cancer mortality.